PARP1 is the most prominent member of the PARP family, accounting for 80%-90% of the enzyme activity, and is a key player in DNA damage repair.

This article summarized the latest R&D progress of Thiocolchicoside, the Mechanism of Action for Thiocolchicoside, and the drug target R&D trends for Thiocolchicoside.

Krystal Biotech publicized that the U.S. FDA has given the green light for the Investigational New Drug application for KB408 to manage alpha-1 antitrypsin deficiency.

This article summarized the latest R&D progress of Tianeptine Sodium, the Mechanism of Action for Tianeptine Sodium, and the drug target R&D trends for Tianeptine Sodium.

Programmed death-ligand 1 (PD-L1) is a protein found on the surface of certain cells in the human body, including immune cells and some cancer cells.

This article summarized the latest R&D progress of Tibolone, the Mechanism of Action for Tibolone, and the drug target R&D trends for Tibolone.

Jazz Pharmaceuticals plc has proclaimed that the EC has approved the commercialization of Enrylaze®(JZP458; a derivative of Erwinia asparaginase or crisantaspase).

This article summarized the latest R&D progress of Tofacitinib Citrate, the Mechanism of Action for Tofacitinib Citrate, and the drug target R&D trends for Tofacitinib Citrate.

PDE3 has the ability to hydrolyze both cAMP and cGMP, but its ability to hydrolyze cAMP is about ten times that of cGMP.

This article summarized the latest R&D progress of Tofisopam, the Mechanism of Action for Tofisopam, and the drug target R&D trends for Tofisopam.

Leucid Bio announced today its UK MHRA-approved CTA to commence Phase 1/2 AERIAL clinical trials of its drug, LEU011, for treating adult patients with relapsed or resistant solid tumours.

This article summarized the latest R&D progress of Zanidatamab, the Mechanism of Action for Zanidatamab, and the drug target R&D trends for Zanidatamab.